Morphine Sulfate Bristol Laboratories (Morphine Sulfate)

Morphine Sulfate is used to manage pain conditions that involve the opioid pathway.

• Severe acute pain: provides rapid, potent analgesia for intense, short‑term pain episodes.
• Post‑operative pain: controls pain after surgical procedures to facilitate recovery.
• Cancer‑related pain: offers sustained relief for malignant disease‑associated pain.

• Morphine Sulfate acts as a full agonist at mu‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and inhibition of pain signal transmission. The resultant analgesic and sedative effects arise from modulation of nociceptive pathways in the brain and spinal cord.

Morphine Sulfate may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea
• Constipation
• Drowsiness or sedation
• Pruritus (itching)

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Adrenal insufficiency
• Anaphylactic reaction

When prescribing Morphine Sulfate, clinicians should observe several safety considerations.

• Dose titration: adjust based on analgesic response and tolerability.
• Respiratory monitoring: observe for depression, especially in opioid‑naïve patients.
• Concurrent CNS depressants: avoid or use with caution due to additive effects.
• Renal or hepatic impairment: consider dose reduction and close monitoring.
• Pregnancy and lactation: use only if benefits outweigh potential risks to mother and fetus.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Morphine Sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Respiratory depressants (e.g., benzodiazepines): additive risk of life‑threatening respiratory depression.
• MAO inhibitors: may cause severe hypotension and serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase morphine plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Diuretics: can enhance hypotensive effects of morphine.
• Anticholinergic agents: may worsen opioid‑induced constipation.